- Home
- AKA vs STTK Comparison
AKA vs STTK Comparison
Compare AKA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- STTK
- Stock Information
- Founded
- AKA 2018
- STTK 2016
- Country
- AKA United States
- STTK United States
- Employees
- AKA N/A
- STTK N/A
- Industry
- AKA Catalog/Specialty Distribution
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- STTK Health Care
- Exchange
- AKA Nasdaq
- STTK Nasdaq
- Market Cap
- AKA 110.4M
- STTK 112.6M
- IPO Year
- AKA 2021
- STTK 2020
- Fundamental
- Price
- AKA $9.75
- STTK $2.35
- Analyst Decision
- AKA Strong Buy
- STTK Hold
- Analyst Count
- AKA 3
- STTK 6
- Target Price
- AKA $24.33
- STTK $2.67
- AVG Volume (30 Days)
- AKA 3.8K
- STTK 548.5K
- Earning Date
- AKA 11-06-2025
- STTK 11-13-2025
- Dividend Yield
- AKA N/A
- STTK N/A
- EPS Growth
- AKA N/A
- STTK N/A
- EPS
- AKA N/A
- STTK N/A
- Revenue
- AKA $598,107,000.00
- STTK $2,997,000.00
- Revenue This Year
- AKA $7.29
- STTK N/A
- Revenue Next Year
- AKA $4.10
- STTK N/A
- P/E Ratio
- AKA N/A
- STTK N/A
- Revenue Growth
- AKA 7.67
- STTK N/A
- 52 Week Low
- AKA $7.00
- STTK $0.69
- 52 Week High
- AKA $27.47
- STTK $2.49
- Technical
- Relative Strength Index (RSI)
- AKA 40.84
- STTK 66.63
- Support Level
- AKA $9.31
- STTK $2.13
- Resistance Level
- AKA $10.58
- STTK $2.49
- Average True Range (ATR)
- AKA 0.53
- STTK 0.22
- MACD
- AKA -0.05
- STTK -0.02
- Stochastic Oscillator
- AKA 26.87
- STTK 80.82
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.